| Young Enough to Undergo Allogeneic Transplantation for Myelodysplastic Syndromes?: Considering the Results of the Medicare Coverage With Evidence Development Study |
|
JAMA Oncology |
Myelodysplastic Syndromes (MDS) |
| Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients With Myelodysplastic Syndromes: Results of a Large Web-Based Survey |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Why Hurry Up and Wait? Transplantation in Lower-Risk Myelodysplastic Syndromes |
|
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation |
Myelodysplastic Syndromes (MDS) |
| Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR study |
|
Journal of Hematology & Oncology |
Myelodysplastic Syndromes (MDS) |
| Where There's Smoke, There's Fire: Inflammation Drives MDS |
|
Trends in immunology |
Myelodysplastic Syndromes (MDS) |
| What causes aplastic anaemia? |
|
Leukemia |
Aplastic Anemia |
| What are the most important quality of life domains for patients with aplastic anemia and paroxysmal nocturnal hemoglobinuria? |
|
Annals of Hematology |
Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseases |
|
Internal and Emergency Medicine |
Myelodysplastic Syndromes (MDS) |
| Venetoclax and Hypomethylating Agents (HMAs) Induce High Response Rates in MDS, Including Patients After HMA Therapy Failure |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
